Search
What are you looking for?
Start main content

Press Releases

Press Releases

https://www.med.cuhk.edu.hk/press-releases/cuhk-dissects-lung-carcinoma-at-single-cell-resolution-uncovering-a-new-mechanism-for-tumour-formation
https://www.med.cuhk.edu.hk/press-releases/cuhk-dissects-lung-carcinoma-at-single-cell-resolution-uncovering-a-new-mechanism-for-tumour-formation

CUHK dissects lung carcinoma at single-cell resolution uncovering a new mechanism for tumour formation

Tumour formation is a multistep and complex process and the underlying mechanism behind it is still largely unclear. A new study conducted by The Chinese University of Hong Kong’s (CUHK) Faculty of Medicine (CU Medicine) dissected the dynamics of lung cancer at single-cell resolution and successfully discovered a new mechanism for tumour formation via “macrophage-myofibroblast transition (MMT)”. Their preclinical work demonstrated its therapeutic implication for treating lung cancer in this first study to define a pathogenic role of MMT in cancer. The findings have been published in a high-impact international scientific journal Advanced Science.

 

Professor Patrick Ming Kuen TANG, Dr. Philip Chiu Tsun TANG, Professor Hui Yao LAN and Professor Ka Fai TO

A new study conducted by CU Medicine dissected the dynamics of lung cancer at single-cell resolution and successfully discovered a new mechanism for tumour formation via “macrophage-myofibroblast transition (MMT)”. The finding may help design precise treatment plans for lung cancer. Members of the research team include (from left) Professor Patrick Ming Kuen TANG, Assistant Professor and Dr. Philip Chiu Tsun TANG, Postdoctoral Fellow from the Department of Anatomical and Cellular Pathology, Professor Hui Yao LAN, Choh-Ming Li Research Professor of Biomedical Sciences from the Department of Medicine and Therapeutics, and Professor Ka Fai TO, Chairman of the Department of Anatomical and Cellular Pathology at CU Medicine.

Better understanding of tumour microenvironment at single-cell resolution accelerates therapeutic development

 

Cancer-associated fibroblasts (CAFs), the most abundant cell type in the tumour microenvironment, are important for tumour formation and progression including angiogenesis, immunosuppression, metastasis, and drug resistance. However, CAFs are highly heterogeneous and multifunctional and contain both “good” (anticancer) and “bad” (protumoral) subpopulations, making them difficult to target. 

 

Single-cell RNA sequencing is an emerging technology to extract the genetic profile of every cell in a tissue sample with high precision. It serves as a perfect tool for the research team to capture the dynamics of the tumour microenvironment which may lead to the discovery of a new therapeutic strategy for targeting CAFs.

 

Professor Patrick Ming Kuen TANG, Assistant Professor from the Department of Anatomical and Cellular Pathology at CU Medicine said, “Single-cell RNA sequencing allows us to observe the dynamics of the tumour microenvironment in an unexplored dimension at the transcriptome level with single-cell resolution, and to distinguish between the “good” and “bad” cells which cannot easily be done by the conventional identification method with scalpel and microscope. It helps us to design precise treatment plans.” 

 

First study to define a pathogenic role of “Macrophage-Myofibroblast Transition” in cancer

 

The mechanism by which immune cells, “macrophages”, are directly transformed into pathogenic myofibroblasts due to long-term overactivation is called MMT. This study further discovered that macrophages can also transform into protumoral CAFs in the tumour microenvironment via MMT for promoting tumour growth. The research team had previously discovered the association of MMT in kidney disease progression, and this is the first study to define a pathogenic role of MMT in cancer.  

 

Dr. Philip Chiu Tsun TANG, Postdoctoral Fellow from the Department of Anatomical and Cellular Pathology at CU Medicine explained, “The advanced bioinformatics strategies pseudotime and RNA velocity allow us to capture the entire developmental process of the macrophages in lung cancer with the single-cell RNA sequencing dataset.” Dr. Tang has recently been awarded the UGC Postdoctoral Fellow Scheme 2021/22 and Young Investigator Award of the Hong Kong Society for Immunology 2021 for this discovery.

 

In addition, the team further identified a transcription factor Smad3 as the key regulator for initiating MMT in non-small-cell lung carcinoma by gene network analysis. They demonstrated that genetic or pharmaceutical inhibition of macrophage Smad3 effectively blocks MMT leading to tumour regression in mice, representing a potential therapeutic target for precisely eliminating the “bad” CAFs. 

 

Professor Hui Yao LAN, Choh-Ming Li Research Professor of Biomedical Sciences from the Department of Medicine and Therapeutics at CU Medicine said, “MMT was discovered from renal fibrosis in 2014 and there are still a lot of possibilities for this novel mechanism in human diseases. Our next step is to develop its precision therapeutics for clinical use.” 

 

Professor Ka Fai TO, Chairman of the Department of Anatomical and Cellular Pathology at CU Medicine added, “Although T-cell based immunotherapy performs well in leukaemia, less than 30% of lung cancer patients respond to it. A better understanding of the tumour microenvironment will improve the efficiency of immunotherapy for solid cancers, possibly by targeting the MMT.” 

 

Article cover

Findings have been published in high-impact international scientific journal Advanced Science.

This study was supported by the Hong Kong Research Grants Council, Faculty Innovation Award from CU Medicine, the State Key Laboratory of Translational Oncology, the Guangdong-Hong Kong-Macao-Joint Labs Programme from the Guangdong Science and Technology Department, and Lui Che Woo Institute of Innovative Medicine (CARE programme). Other main contributors to this study include Professor Alfred Sze-Lok CHENG, Professor Tin-Lap LEE, Professor Kam-Tong LEUNG, Professor Anna Chi-Man TSANG, and PhD student Jeff Yat-Fai CHUNG from CU Medicine. The original study can be accessed here: https://onlinelibrary.wiley.com/doi/10.1002/advs.202270005   

More Press Releases

CUHK Uncovers Novel Immune Escape Mechanism of Cancer Opening Up New Direction for Cancer Immunotherapy

CUHK Uncovers Novel Immune Escape Mechanism of Cancer Opening Up New Direction for Cancer Immunotherapy

Research
CUHK unlocks the secret of cancer pain  Identifying a new therapeutic key to ending the sorrow

CUHK unlocks the secret of cancer pain Identifying a new therapeutic key to ending the sorrow

Research
CUHK Uncovers How Immune Cells Turn Bad A New Hope for Kidney Patients

CUHK Uncovers How Immune Cells Turn Bad A New Hope for Kidney Patients

Research
CUHK Unravels the Whole Genome of Nasopharyngeal Cancer A Great Leap Forward in Personalized Medicine Development

CUHK Unravels the Whole Genome of Nasopharyngeal Cancer A Great Leap Forward in Personalized Medicine Development

Research
CUHK study sheds light on novel mechanism and treatment of acute kidney injury in COVID-19 patients

CUHK study sheds light on novel mechanism and treatment of acute kidney injury in COVID-19 patients

Research
CUHK Uncovers a New Strategy to Turn “Cold” Liver Tumour “Hot” Leading to an Effective and Durable Combined Immunotherapy

CUHK Uncovers a New Strategy to Turn “Cold” Liver Tumour “Hot” Leading to an Effective and Durable Combined Immunotherapy

Research
CUHK to Commence the Next-Generation Clinical Trials of CAR-T Cell Therapy for Haematological Malignancy

CUHK to Commence the Next-Generation Clinical Trials of CAR-T Cell Therapy for Haematological Malignancy

Research
CUHK first discovers obese patients with diabetes and fluctuating blood glucose control had a high cancer risk while patients with diabetes treated with a common class of blood pressure lowering drug had a low cancer risk

CUHK first discovers obese patients with diabetes and fluctuating blood glucose control had a high cancer risk while patients with diabetes treated with a common class of blood pressure lowering drug had a low cancer risk

Research
CUHK’s study sees a rising trend of multiple myeloma incidence,  particularly in older males from high-income countries

CUHK’s study sees a rising trend of multiple myeloma incidence, particularly in older males from high-income countries

Research
CUHK finds the largest rise in incidence of Hodgkin lymphoma in Asia Rising trend of male incidence means Hong Kong tops the world

CUHK finds the largest rise in incidence of Hodgkin lymphoma in Asia Rising trend of male incidence means Hong Kong tops the world

Research
Study by CUHK medical students identifies STK3 kinase as a driver in gastric cancer

Study by CUHK medical students identifies STK3 kinase as a driver in gastric cancer

Education
CUHK Study Finds Half of Childhood Cancer Survivors Used Complementary and Alternative Medicine

CUHK Study Finds Half of Childhood Cancer Survivors Used Complementary and Alternative Medicine

Research
Insights into B-cells and GPR18 Gene Expression by CU Medicine team  Improve Prediction of Survival in Multiple Cancer Types

Insights into B-cells and GPR18 Gene Expression by CU Medicine team Improve Prediction of Survival in Multiple Cancer Types

Research
CU Medicine Team Discovers a Novel Prognostic Biomarker for a Doubled Survival in Head and Neck Cancer

CU Medicine Team Discovers a Novel Prognostic Biomarker for a Doubled Survival in Head and Neck Cancer

Research
CUHK in collaboration with West China School of Medicine co-Led World’s First-in-human Clinical Trial using CRISPR technology for lung cancer Confirmed gene-edited T-Cell Therapy is Safe and Feasible in Treatment of Advanced NSCLC

CUHK in collaboration with West China School of Medicine co-Led World’s First-in-human Clinical Trial using CRISPR technology for lung cancer Confirmed gene-edited T-Cell Therapy is Safe and Feasible in Treatment of Advanced NSCLC

Research
CUHK Successfully Conducts Asia-Pacific’s First Hybrid Operating Room Non-invasive Bronchoscopic Microwave Ablation to Treat Lung Cancer

CUHK Successfully Conducts Asia-Pacific’s First Hybrid Operating Room Non-invasive Bronchoscopic Microwave Ablation to Treat Lung Cancer

Surgical advancement
李嘉誠基金會啟動《愛能助》兒童癌症項目 資助兒童罕見癌症 (Chinese version only)

李嘉誠基金會啟動《愛能助》兒童癌症項目 資助兒童罕見癌症 (Chinese version only)

Donation
Professor Tony MOK Honoured with the ESMO Lifetime Achievement Award Recognising His Global Leadership in Defining Lung Cancer Treatment Standard

Professor Tony MOK Honoured with the ESMO Lifetime Achievement Award Recognising His Global Leadership in Defining Lung Cancer Treatment Standard

Awards and honors
CUHK Receives an International Cancer Care Team Award Nominated by Patients

CUHK Receives an International Cancer Care Team Award Nominated by Patients

Awards and honors
CUHK Launches Multi-Cancer Prevention Programme Providing Free Screening to 10,000 HK Residents to Study Links with Obesity

CUHK Launches Multi-Cancer Prevention Programme Providing Free Screening to 10,000 HK Residents to Study Links with Obesity

Health Campaign
CUHK-led Global Study Sees Improvement in Overall Survival in Patients with Advanced Lung Cancer

CUHK-led Global Study Sees Improvement in Overall Survival in Patients with Advanced Lung Cancer

Research
CUHK Study Sees Increasing Global Incidence of Colorectal Cancer Among Younger People

CUHK Study Sees Increasing Global Incidence of Colorectal Cancer Among Younger People

Research
CUHK Pioneers Early Lung Cancer Treatment with Hybrid Operating Room Image Guided Electromagnetic Navigation Bronchoscopy

CUHK Pioneers Early Lung Cancer Treatment with Hybrid Operating Room Image Guided Electromagnetic Navigation Bronchoscopy

Surgical advancement
A CUHK-led International Study Demonstrates Immune-checkpoint Inhibitor Is Effective in Patients with Advanced Nasopharyngeal Cancer

A CUHK-led International Study Demonstrates Immune-checkpoint Inhibitor Is Effective in Patients with Advanced Nasopharyngeal Cancer

Research
CUHK Study Proves Ablative Chemoembolization Doubles the Progression-Free Survival for Liver Cancer Patients

CUHK Study Proves Ablative Chemoembolization Doubles the Progression-Free Survival for Liver Cancer Patients

Research
CUHK Research Receives Recognitions by Top Medical Journals

CUHK Research Receives Recognitions by Top Medical Journals

Awards and honors
CUHK-HKU Study on Multi-gene Mutation-Drug Matching for Recurrent Ovarian Cancer Patients Providing Free Pharmacogenomic Analysis for 100 Patients in Hong Kong

CUHK-HKU Study on Multi-gene Mutation-Drug Matching for Recurrent Ovarian Cancer Patients Providing Free Pharmacogenomic Analysis for 100 Patients in Hong Kong

Research
CUHK Completes a 20,000-person Plasma DNA Screening Study of Nasopharyngeal Cancer, and Finds a Dramatic Shift to Early Stage Cancers

CUHK Completes a 20,000-person Plasma DNA Screening Study of Nasopharyngeal Cancer, and Finds a Dramatic Shift to Early Stage Cancers

Research
CUHK-led Research Confirms Novel Targeted Therapy Doubles the Effectiveness of Current Standard Treatment for ALK-Positive Lung Cancer

CUHK-led Research Confirms Novel Targeted Therapy Doubles the Effectiveness of Current Standard Treatment for ALK-Positive Lung Cancer

Research
CUHK Professor Hui Yao LAN’s Research on Chronic Kidney Disease Wins First Prize in Chinese Medical Science and Technology Award

CUHK Professor Hui Yao LAN’s Research on Chronic Kidney Disease Wins First Prize in Chinese Medical Science and Technology Award

Awards and honors
The 7th Palliative Care Symposium for Health Care Workers in Chinese Population: ‘Palliative Care in the Community’

The 7th Palliative Care Symposium for Health Care Workers in Chinese Population: ‘Palliative Care in the Community’

Symposium
CUHK Succeeded in Animal Study and Clinical Case of Percutaneous Nanoknife New Breakthrough in Cancer Treatment

CUHK Succeeded in Animal Study and Clinical Case of Percutaneous Nanoknife New Breakthrough in Cancer Treatment

Research
CUHK Discovers Innovative ‘Flow Diverters’ (Pipeline) as Effective Treatment for Cerebral Aneurysms in Asia’s First Clinical Study in Collaboration with Seven Medical Centres

CUHK Discovers Innovative ‘Flow Diverters’ (Pipeline) as Effective Treatment for Cerebral Aneurysms in Asia’s First Clinical Study in Collaboration with Seven Medical Centres

Research
CUHK and HKU Host the 5th Annual Palliative Care Symposium for Health Care Workers in Chinese Population

CUHK and HKU Host the 5th Annual Palliative Care Symposium for Health Care Workers in Chinese Population

Symposium
CUHK Pioneers Innovative Computer Assisted Tumor Surgery for Bone Cancer Patients

CUHK Pioneers Innovative Computer Assisted Tumor Surgery for Bone Cancer Patients

Surgical advancement
Bowel Cancer Will Become Top Cancer in Hong Kong CUHK Introduces Colon Pill Camera to Prevent Bowel Cancer

Bowel Cancer Will Become Top Cancer in Hong Kong CUHK Introduces Colon Pill Camera to Prevent Bowel Cancer

Surgical advancement
The Chinese University of Hong Kong Nethersole School of Nursing hosts the Fifth Pan-Pacific Nursing Conference and Seventh Nursing Symposium on Cancer Care

The Chinese University of Hong Kong Nethersole School of Nursing hosts the Fifth Pan-Pacific Nursing Conference and Seventh Nursing Symposium on Cancer Care

Symposium
Predicting Your Colorectal-polyp Risk with CUHK Colorectal-polyp Prediction Index (CU-CPI)

Predicting Your Colorectal-polyp Risk with CUHK Colorectal-polyp Prediction Index (CU-CPI)

Clinical service

Our Expert List

Many experts under the Faculty of Medicine are available for media interview.
Please click here for the expert list or contact us.